PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться
  1. Биоэквивалентность. ANOVA. Часть I.
  2. Биоэквивалентность. ANOVA. Часть II.
  3. Биоэквивалентность. ANOVA. Пример.
  4. Phoenix WinNonlin проект подтверждения метода.
  5. Биоэквивалентность. Расчет выборки.
  6. Пример расчета выборки с помощью итеративной процедуры.
  7. Пример расчета pooled CV и доверительного интервала для CV.
  8. Фармакокинетика. Основные понятия.
  9. Фармакокинетика. Основные понятия. Пример расчета ФК параметров.
  10. Phoenix WinNonlin проект подтверждения примера расчета ФК параметров.
  11. Планирование клинического исследования.
  12. Биоэквивалентность. ANOVA. Часть III.
  13. Таблица данных для тестового расчета.

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170806-WA0026
20170731 192225
20180131 184310
IMG-20170806-WA0047
20180814 175807
20170730 175904
  • Human medicines European public assessment report (EPAR): Hyftor, sirolimus, Date of authorisation: 15/05/2023, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): MenQuadfi, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 18/11/2020, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Date of authorisation: 05/04/2006, Revision: 34, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Date of authorisation: 22/11/2018, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Date of authorisation: 17/12/2020, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Rilonacept FGK Representative Service GmbH , rilonacept, Status: Application withdrawn
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Procedural guidance to scientific committeesꞌ members and experts on completing the European Medicines Agencyꞌs declaration of interests in the Experts Management Tool
    Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Orfadin, nitisinone, Date of authorisation: 21/02/2005, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Neoatricon, dopamine hydrochloride, Date of authorisation: 27/05/2024, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 24, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-04
  • Information by Drug Class
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
  • Registered Outsourcing Facilities
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
  • AFLURIA , AFLURIA SOUTHERN HEMISPHERE
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-03 By FDA
  • Exela Pharma Sciences, LLC - 709859 - 07/02/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-03 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.